1. Penpulimab and lenalidomide in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx regimen) is safe, tolerable, and shows antitumour activity ...
1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 ...
1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
